Osimertinib following definitive chemoradiotherapy as the new standard of care for patients with unresectable, stage III, EGFR-mutant NSCLC
Results of the randomised phase III LAURA study, presented during the plenary session at ASCO 2024, establish consolidation therapy with osimertinib as the new standard of care following definitive chemoradiotherapy (CRT) in patients with unresectable stage III, EGFR-mutant non-small cell lung cancer (NSCLC). Compared to placebo, consolidation ther